About this trial
Deep surgical site infection (DSSI) is one of the most challenging complications for spinal surgeons and can lead to a poor clinical outcome. This ambispective study was designed to examine the effect of vancomycin powder mixed with autogenous bone graft and bone substitute on preventing deep surgical site infection (DSSI) in degenerative lumbar fusion surgeries as well as any interference with bony fusion.
Eligibility criteria
Qualifiers
Patients who have instrumented spine fusion surgery due to failed conservative treatment (bed rest, medication, rehabilitation programs) for 3 to 6 months
Patients who are willing to sign the surgical permit after the surgeon explains all surgical procedures along with the surgical risks
Patients who fully understand the surgical procedures as well as the surgical risks and are willing to sign the surgical permit and the inform consent
Patients who agree one more blood withdrawal after operation
Disqualifiers
Patients who agree to accept the spine surgery but do not agree to sign the inform consent
Patients who have allergic reaction to vancomycin
Trial design
Treatments tested in this trial
- with U-VANCO (vancomycin hydrochloride)
- without U-VANCO (vancomycin hydrochloride)